Project Grant R01DA063053
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Columbia University a $2.94 million Project Grant on September 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a longitudinal study examining the impact of cannabis use disorder (CUD) and its treatment on opioid-related health consequences among Veterans Health Administration (VHA) patients through May 31, 2030. The research will leverage de-identified VHA data from 4.5 million...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Feinstein Institutes For Medical Research a Project Grant of $1,205,548 (awarded July 15, 2025, with completion by March 31, 2030) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on transposable element expression in the context of HIV-1 and cannabis use. The project, titled "Single Cell Dark Matter in the Context of HIV and Substance Use," develops and applies a...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Medical University of South Carolina a Project Grant totaling $686,692 under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct prospective research on cannabis use reduction and its impact on patient functioning. Initiated on September 1, 2025, and extending through July 31, 2030, this eight-week clinical trial will enroll 176 adults aged 18 and older with Cannabis Use Disorder...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Boston Children's Hospital a $489,500 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning June 1, 2025 and concluding May 31, 2027. This research initiative develops and validates remote oral fluid testing procedures to assess cannabis non-use as a key outcome measure in clinical trials targeting younger adults aged 18-30 years with cannabis use disorder (CUD). The project...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of California, San Diego a $1.5 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct translational and cross-species research examining the effects of cannabis use on mitochondrial function in people with HIV (PWH). The award, effective June 1, 2026, through April 30, 2031, supports an integrated research program combining clinical observation with...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $731,879 project grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective May 1, 2026 through February 28, 2031. This research initiative will investigate the impact of cannabis use on the NLRP3 inflammasome in people with HIV (PWH), with particular focus on understanding how cannabinoid exposure modulates immune activation...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Vermont & State Agricultural College a $387,291 Project Grant effective March 1, 2026, through December 31, 2030, under the Drug Use and Addiction Research Programs (CFDA 93.279). This research initiative delivers a comprehensive neuroimaging analysis examining developmental vulnerability windows for cannabis exposure and its causal relationships to neurodevelopment and behavioral outcomes....
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Children's Hospital of Philadelphia Research Institute a $456,268 Project Grant on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a two-year research investigation examining antioxidant and cerebral blood flow profiles in people living with HIV (PWH) who use marijuana. The project will utilize advanced edited magnetic resonance spectroscopy (MRS) to assess glutathione...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA), under its Drug Use and Addiction Research Programs (CFDA 93.279), awarded The Johns Hopkins University a $194,271 Project Grant effective May 1, 2026 through April 30, 2028. This R21 Exploratory/Developmental Research award supports the development and optimization of rodent models designed to advance medications development for cannabis use disorder (CUD). The project will establish reliable drug discrimination and...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Massachusetts Medical School a $1.74 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning July 15, 2025, with completion targeted for March 31, 2030. This award supports research focused on the discovery and functional characterization of long non-coding RNAs (lncRNAs) in opioid use disorder (OUD) within the context of HIV at single-cell resolution. The...
The National Institute on Drug Abuse (NIDA) awarded Boston University Medical Campus a Project Grant of $732,747 under the Drug Use and Addiction Research Programs (CFDA 93.279) on June 15, 2026, with an ultimate completion date of March 31, 2031. This award supports research quantifying the health effects of cannabis use and cannabis use disorder (CUD) on geriatric syndromes and HIV outcomes through causal effects analysis. The research utilizes longitudinal data from the Veterans Aging Cohort Study (VACS-HIV, approximately 180,000 veterans) and the Mt. Sinai HIV Cohort (approximately 850,000 participants) to examine the association between CUD and incident falls, fractures, delirium, dementia, and antiretroviral therapy (ART) adherence among aging people living with HIV. The primary products and services delivered under this grant include causal inference analyses estimating the direct effects of cannabis use on geriatric syndromes and ART outcomes, with analysis stratified between veteran and non-veteran populations to assess generalizability. The research team will employ electronic health record data, informatics expertise, and epidemiological methods to generate evidence on cannabis-associated harms among aging persons with HIV—a population identified as particularly vulnerable to adverse outcomes from higher-potency cannabis products. Findings will contribute to the NIDA priority of understanding substance use's role in HIV pathogenesis and inform policy discussions regarding cannabis legalization and its effects on clinical outcomes in this vulnerable patient population.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $732.7k | 6/1/26 |